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Key Points
•We have developed
a novel drug-delivery
system that delivers
cancer therapeutics
and blocks CXCR4’s
interaction with
CXCL12.
• The drug-delivery sys-
tem is modular and
versatile, allowing it to
be tailored to other
hematological cancers
in which CXCR4 is
implicated.
CXC chemokine receptor 4 (CXCR4) is overexpressed by a broad range of hematological
disorders, and its interactionwithCXC chemokine ligand 12 (CXCL12) is of central importance
in the retention and chemoprotection of neoplastic cells in the bone marrow and lymphoid
organs. In this article, we describe the biological evaluation of a new CXCR4-targeting and
-antagonizing molecule (BAT1) that we designed and show that, when incorporated into
a liposomal drug delivery system, it can be used to deliver cancer therapeutics at high levels
to chronic lymphocytic leukemia (CLL) cells. CXCR4 targeting and antagonism by BAT1 were
demonstrated alone and following its incorporation into liposomes (BAT1-liposomes).
Antagonism of BAT1 against the CXCR4/CXCL12 interaction was demonstrated through
signaling inhibition and function blocking: BAT1 reduced ERK phosphorylation and cell
migration to levels equivalent to those seen in the absence of CXCL12 stimulation (P, .001).
Specific uptake of BAT1-liposomes and delivery of a therapeutic cargo to the cell nucleus was
seen within 3 hours of incubation and induced significantly more CLL cell death after
24 hours than control liposomes (P 5 .004). The BAT1 drug-delivery system is modular,
versatile, and highly clinically relevant, incorporating elements of proven clinical efficacy.
The combined capabilities to block CXCL12-induced migration and intracellular signaling
while simultaneously delivering therapeutic cargo mean that the BAT1-liposome drug-
delivery system could be a timely and relevant treatment of a range of hematological
disorders, particularly because the therapeutic cargo can be tailored to the disease being
treated.
Introduction
Drug-delivery systems are nanoscale objects that store therapeutic agents, releasing them upon uptake
into target cells. Targeting ligands (most commonly binding a receptor overexpressed on the cell) can be
used to decorate the drug-delivery system and provide specificity for target cells, such as cancer cells.1-3
In some instances, the interaction between targeting ligands and cell receptors can be further exploited
to block or modify important cell functions, achieving additional chemosensitizing or disease-modifying
effects. The most widely used drug-delivery vehicles in clinical practice are liposomes. Nontargeted
liposomes encapsulating drugs such as doxorubicin, cytarabine, or vincristine have been used in the
treatment of hematological cancers,4-6 and research into the use of targeting agents in hematological
malignancies is ongoing7-9; however, the field remains underdeveloped. In this article, we present the
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use of the novel CXC chemokine receptor 4 (CXCR4)–targeting
drug BAT1 (referred to as molecule 1 in our prior publication)10
incorporated into liposomes (BAT1-liposomes). We demonstrate
that BAT1-liposomes combine function blocking and effective drug
delivery to primary chronic lymphocytic leukemia (CLL) lympho-
cytes. This highly adaptable system has the potential to be used in
a range of hematological cancers in which CXCR4 plays an
important role.11,12
CXCR4 is overexpressed in .20 cancers, including CLL, where
its role has been studied in depth.13-17 In CLL, CXCR4 plays
a significant role in the interaction between neoplastic cells and
their microenvironment through CXC chemokine ligand 12 (CXCL12),
which is central to the emergence of cells that are resistant to
standard treatment and, therefore, are referred to as the chemo-
protective niche.18-20 Bis(cyclam) compounds are a class of high-
affinity CXCR4 antagonists, with the class-leading drug (plerixafor)
licensed for clinical use.21 In CLL, several studies have found that
plerixafor disrupts lymphocyte interactions within the bone marrow
microenvironment,14,20,22 leading to increased CLL cell sensitiza-
tion to standard therapies. Promising results from clinical trials using
plerixafor in combination therapies suggest that bis(cyclam) com-
pounds may lead to improved patient outcomes when administered
with other therapeutics.23-25
The ability of plerixafor to tightly bind CXCR4 makes it an attrac-
tive choice for use in targeted drug delivery.18,26-29 However,
plerixafor is not readily attached to drug-delivery systems, because
chemical modification occurs primarily through the molecule’s
cyclam groups, which significantly reduces its affinity to CXCR4.28
To overcome this barrier, we have synthesized a bis(cyclam) com-
pound (BAT1) with a flexible tether attached to the aromatic core
that allows easy conjugation to other molecules while retaining
a high affinity to CXCR410 (Figure 1A). In this article, we show that,
following conjugation to nanoparticles, BAT1 can be used to target
liposomally encapsulated chemotherapy drugs to CLL lymphocytes
while retaining the capability to block intracellular signaling and
migration responses of CLL cells to CXCL12.
Methods
General reagents
Unless otherwise stated, all reagents were purchased from Sigma-
Aldrich (Gillingham, United Kingdom). Details about all antibodies,
including their suppliers and the concentrations used, can be found
in supplemental Tables 1 and 2.
Preparation of BAT1 liposomes
BAT1 and the conjugate between BAT1 and cholesterol (BAT1-
cholesterol) were prepared as described previously.10 For analysis,
conjugation to the Cy5-NHS ester was performed as follows: BAT1
(3 mmol) was mixed with Cy5-NHS ester (1 molar equivalent) in
3 mL of Milli-Q water and then stirred overnight at room
temperature. The mixture was purified using high-performance
liquid chromatography (supplemental Methods and data) and
nuclear magnetic resonance and mass spectrometry analysis were
used to confirm conjugation (supplemental Figures 1 and 2). The
reaction can also be performed directly in phosphate-buffered
saline (pH 7.4). Mass spectrometry MS (ESI1) calculated for
C81H137N12O18S3 [M1 3H]
315 553.9773, found: 553.9837 and
calculated for C81H137N12O18S3Na [M1 H1 Na]
21 5 841.9550,
found: 841.9640.
Liposomes were prepared using standard methods30 (supple-
mental Methods and data), incorporating the following phospholi-
pids (PLs): 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dimyristoyl-sn-glycero-3-phospho-L-serine, and 1,2-dimyristoyl-
sn-glycero-3-phospho-(19-rac-glycerol). The z potential of all
preparations was measured in buffer (HEPES buffer: 25 mM with
150 mM NaCl, pH 7.5), at PL concentrations of 10 mM, using
a Malvern Zetasizer Nano ZSP at 25°C. Dynamic light scattering
(DLS) measurements were performed in Milli-Q water (concentra-
tion: 10 mM of PLs) on a Malvern Zetasizer Nano ZSP 633-nm laser
at 25°C (3 runs of 12 scans per sample) and a scattering angle of
173° using the diffusion barrier method.31 Doxorubicin was actively
loaded into DOPC liposomes using a pH gradient under standard
methods32 (supplemental Methods and data), and the quantity
loaded was quantified using UV–visible absorption spectroscopy
(supplemental Figure 7).
Biological analysis
Cells and culture. Primary human CLL peripheral blood
mononuclear cells (PBMCs) were collected with informed consent
and full Research Ethics Committee (REC) approval: Manchester
REC reference 10/H1017/73, Plymouth REC reference 14/EE/
1251. Details of disease characteristics and cases are provided in
supplemental Table 3. Cells were cultured at 37°C and 5% CO2
using RPMI 1640 medium supplemented with 10% fetal calf serum,
1% L-glutamine, and 1% penicillin streptomycin, with cell densities
between 1 and 4 3 106 cells per milliliter, depending on the assay.
CLL PBMCs were used without further purification.
In some liposomal-uptake assays (indicated in “Results” and in the
figure legends), cells were cocultured with murine fibroblasts stably
transfected with the CD40 ligand (CD40L murine fibroblasts;
donated by C.V.H.). This coculture reproduces some of the stromal
interactions present in vivo and alters membrane CXCR4 expres-
sion (supplemental Figure 5). Experiments were performed by
coculturing the CLL cells with CD40L murine fibroblasts at 70%
confluency for 24 hours before incubation with the liposomes.
Immunohistochemistry. Sections of normal or CLL tissue
were kindly donated by Richard Byers (Division of Cancer Sciences,
University of Manchester). Preparation used standard deparaffini-
zation (Histo-Clear II; Scientific Laboratory Supplies, Nottingham,
United Kingdom) and antigen retrieval (10 mM sodium citrate at
65°C; Thermo Fisher, Altrincham, United Kingdom) before
blocking with H2O2 and protein block (Mouse and Rabbit Specific
HRP/DAB [ABC] Detection IHC Kit; Abcam PLC, Cambridge,
United Kingdom). Immunostaining used CXCR4 or CXCR7
antibodies overnight at 4°C.
Flow cytometry. Analysis used a BD FACSCanto II flow
cytometer and BD FACSDiva and FlowJo v10 software.
Competition assays. After culturing overnight, cells were in-
cubated for 3 hours with BAT1 or plerixafor (R&D Systems,
Abingdon, United Kingdom). Concentrations are indicated in the
figures. CXCR4 and CXCR7 antibody staining (15 minutes, room
temperature) was performed, followed by fixation with 1% para-
formaldehyde. BAT1-Cy5 cell-targeting assay. Cells were incu-
bated with BAT1-Cy5 for 3 hours (0-10 mM), washed, and analyzed
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using flow cytometry. Controls. Plerixafor (R&D Systems) pre-
treatment (20 mM), free Cy5, vehicle (compound-free buffer).
Viability assays. Doxorubicin was used in a number of the
assays and has a broad fluorescence emission profile, which
interferes with the use of fluorescent probes for cell death.
Therefore, the positions of live, early apoptotic, and dead cells on
scatter plots were determined using propidium iodide and annexin-
FITC staining (supplemental Figure 8) and were found to be
consistent across all cases tested; this confirmed that cell death
occurred by an apoptotic, rather than a necrotic, mechanism.
Therefore, all viability assays in this study used scatter plots to
determine the proportion of dead cells within the population.
Measurements of cell viability were performed at 24 hours, which is
consistent with the time required for apoptosis to be induced
following disruption of the interaction between CLL lymphocytes
and supportive cells of monocyte lineage.20,33
Western blot. Cells were cultured overnight and then
exposed to BAT1, plerixafor, or vehicle for 3 hours. Cells were
then incubated with 200 ng/mL CXCL12 for 5 minutes at
37°C. Cell pellets were extracted with radioimmunoprecipitation
assay buffer (recipe in supplemental Methods and data) before
electrophoresis and immunoblotting. Immunoblotting for CXCR4
and CXCR7 was performed without stimulation and used appro-
priate modifications for tetraspan proteins. Full details are
provided in supplemental Methods and data. Visualization used
horseradish peroxidase–conjugated secondary antibody, fol-
lowed by Amersham ECL Prime Western Blotting Detec-
tion Reagent (GE Healthcare Life Sciences, Amersham,
United Kingdom), with a Molecular Imager ChemiDoc XRS1
System (Bio-Rad, Watford, United Kingdom). Image analysis
was performed using Image Lab Software (Bio-Rad) and ImageJ
(v.1.52a; National Institutes of Health, Bethesda, MD). Minor
changes to image background levels were applied equally to
optimize blot visibility in figures.
Messenger RNA analysis. Results were derived from
a wider microarray study on these cells. Briefly, pellets from cells
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Figure 1. Molecular structures of the compounds
used in this article, with the symbols used for
schematic representations. (A) Structure of BAT1, and
its derivatives, BAT1-Cy5 (fluorescently labeled BAT1
conjugate) and BAT1-cholesterol (used to decorate lip-
osomes with BAT1). (B) Structure of the fluorescently la-
beled lipid, TopFluor, which was used to label liposomal
membranes for ease of tracking. (C) Structure of doxoru-
bicin, the drug cargo loaded into liposomes and delivered
using BAT1 targeting.
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cultured overnight as above were lysed and then RNA was
extracted with 100 mL of RLT buffer (Qiagen, Manchester, United
Kingdom), yielding 134 ng/mL RNA. Analysis used an Affymetrix 39
microarray for 20 000 genes (Thermo Fisher) and PUMA 1.2.1
software (University of Manchester).
Immunofluorescence. Cytospin preparations (Thermo Fisher)
of cells, cultured in the presence or absence of drugs, chemokine,
or liposomes (as indicated), were mounted and nuclei were
visualized using a 49,6-diamidino-2-phenylindole (DAPI)–containing
mountant (ProLong Gold Antifade Mountant; Thermo Fisher) and
then examined using an Axio Vert epifluorescent microscope (Zeiss,
Cambridge, United Kingdom) or an IX83 inverted microscope
(Olympus, Southend-on-Sea, United Kingdom) after antibody
staining.
To compare membrane-bound and internal CXCR4 expression,
cells in suspension were incubated with mouse anti-CXCR4 on ice
(30 minutes), washed, and incubated with an anti-mouse secondary
antibody. Samples were then fixed (1% paraformaldehyde) and
cytospun onto glass slides before permeabilization (0.1% Triton
X-100). A second CXCR4 antibody (rabbit anti-human) with an
appropriate secondary antibody was used to visualize internal
CXCR4.
Liposome uptake and cargo release were assessed via fluores-
cence microscopy; decorated and undecorated liposome prepara-
tions incorporated 1% (mol/mol) fluorescently labeled PL (TopFluor
PC) or doxorubicin (supplemental Methods and data). Cells
cultured with decorated or undecorated liposomes were cytospun,
fixed in 1% paraformaldehyde, permeabilized, and stained with
DAPI. Following acquisition, images were deconvolved using
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Figure 2. CLL cells consistently express CXCR4 in the peripheral blood and lymphoid organs, whereas CXCR7 expression is significantly lower, (A) Healthy
tonsil and CLL spleen sections were stained with antibodies against CXCR4 or CXCR7. In normal tonsil, CXCR4 is widely expressed but with noticeably stronger expression
in follicles. In contrast, expression of CXCR7 is weak, and it is expressed primarily by vascular endothelial cells. In organs infiltrated by CLL (shown in spleen), expression of
CXCR4 and CXCR7 is observed across the entire sample. CXCR4 staining in proliferation zones is weaker than in other regions of the sample but is still observed. CXCR7
expression is detected, but it is far weaker than CXCR4, with no strong differences observed between proliferation centers and the surrounding tissue. The insets in the upper
panels are shown at increased magnification in the lower panels. HRP/DAB technique was used with hematoxylin counterstain. Scale bars, 500 mm. (B) Immunoblot showing
relative protein expression levels of CXCR4 and CXCR7 in primary CLL cells, with total ERK1/2 presented as a protein expression control. Densitometric quantification of the
blots is shown with adjustment relative to the protein expression control on each blot. Percentage errors were calculated as the average variation between equivalent blots
across several experiments. (C) Immunocytofluorescence of CXCR4 assessed by flow cytometry using a phycoerythrin-conjugated CXCR4 antibody for a representative case
(shaded graph), with the isotype-control peak shown as a dotted line. (D) Median CXCR4 staining of CLL PBMCs from 10 cases was assessed with flow cytometry using
a phycoerythrin-conjugated CXCR4 antibody (d) compared with isotype control (⃝). The median and range of each distribution are represented by horizontal lines. Strong
CXCR4 expression is consistently observed, although a significant variation in median staining level was also seen.
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Huygens Software (Scientific Volume Imaging). Z-projection and
background correction were performed using ImageJ.
Migration assays. Cells were cultured overnight, incubated
with BAT1, plerixafor, or PBS for 3 hours (concentrations are
indicated in the figures), and then aliquoted into the permeable
inserts of a filter migration plate (Corning Transwell). The receiving
well was filled with complete media (600 mL) containing CXCL12
(200 ng/mL); cells were incubated for 90 minutes at 37°C, and cells
from the lower well were counted without further cell purification
using a fixed acquisition time with a flow cytometer to provide
a cell concentration relative to the positive control (CXCL12, no
antagonist).
Doxorubicin-loaded liposome cell death assay. A
method adapted from Iden and Allen34 was used. Cells cultured
overnight at 4 3 106 cells per milliliter were dosed with decorated
or undecorated doxorubicin-loaded liposomes (dox-liposomes) at
30 to 150 mM (PL), and their viabilities were assessed at 3, 6, and
24 hours. At 3 and 6 hours, cells were washed to remove free
liposomes and cultured in fresh media for the remaining 21 or
18 hours, respectively. At 24 hours, all cells were diluted 1:3, and
their viability was assessed using flow cytometry. Separate experi-
ments investigating cell death at 3 and 6 hours found that no excess
death occurred at these earlier time points (supplemental Figure 9).
Statistical methods
Dose-response curves, aligned dot plots, and cell-migration column
charts were plotted and analyzed using Prism (version 7; GraphPad
Software, La Jolla, CA). For full equations, see supplemental
Methods and data. Statistical analysis used Prism’s in-built analyses
(see figure legends). All flow cytometric data were analyzed as
median fluorescence intensity using FlowJo software v10. Cell
death was normalized with respect to control. Quantification of
relative protein expression after western blot was determined via
densitometry in Fiji without image adjustment.
Results
Synthetic design of the modified bis(cyclam)
drug BAT1
BAT1 was synthesized using a 3-step approach that was devel-
oped and published by the authors using an adapted synthetic
methodology for bis(cyclam) CXCR4-antagonist drugs.10 BAT1
was then modified to produce conjugates that allow functional
targeting of CXCR4-expressing cells (Figure 1A).
A
0.0001 0.001 0.01 0.1 1 10 100
0
20
40
60
80
100
Concentration (M)
%
 C
XC
R4
 st
ain
ing
B
Concentration (M)
0.0001 0.001 0.01 0.1 1 10 100
0
20
40
60
80
100
%
 C
XC
R7
 st
ain
ing
1000 10000
Relative fluorescence units
Re
lat
ive
 c
ou
nt
s
C
Figure 3. BAT1 binds tightly to CXCR4, leading to dose-dependent in-
hibition of antibody binding and delivery of fluorescent cargo. (A)
Phycoerythrin-CXCR4 antibody competition assay against BAT1 (red line) and pler-
ixafor (blue line), assessed using flow cytometry. Primary CLL cells from a representa-
tive case were incubated with BAT1 or plerixafor at concentrations between 0 and
20 mM for 3 hours and then stained with phycoerythrin-conjugated CXCR4
antibodies. Experiment was performed in triplicate, and the mean was taken of the
medians of each fluorescent distribution; errors were calculated as standard de-
viation of the mean. Dose-response curve fitted using a modified Hill equation, as
detailed in supplemental Methods and data. A dose-dependent reduction in fluores-
cence was observed for BAT1 and plerixafor, with IC50(BAT1) 5 138 nM and
IC50(plerixafor) 5 11.7 nM. (B) Analogous PerCP-CXCR7 antibody competition
assay against BAT1 (red line) and plerixafor (black line). A dose-dependent re-
duction in antibody-staining was not observed for BAT1 or plerixafor. Fluorescence
due to bound anti-CXCR7 antibody decreased at the highest concentrations of
Figure 3. (continued) plerixafor or BAT1, but this decrease is within the measure-
ment error, determined using the standard deviation of the mean. (C) Flow cyto-
metric analysis of dose-dependent and selective BAT1-Cy5 targeting to CLL cells.
Primary CLL cells were incubated with Cy5-conjugated BAT1 at 5 mM (solid red
line) and 10 mM (solid blue line) for 3 hours. To demonstrate selectivity, the cells
were also preincubated with 20 mM plerixafor as a comparison (dashed lines).
BAT1-Cy5 was found to bind to CLL cells in a dose-dependent manner, and cells
preincubated with 20 mM plerixafor present significantly reduced fluorescence, as
indicated by the arrow. These data indicate that BAT1 can be used to specifically
target functional molecules, such as dyes, to CXCR4-expressing cells.
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Figure 4. BAT1 acts as a pure antagonist against CXCL12, reducing migration along the chemokine gradient and cell viability in vitro. (A) Fluorescence
microscopy analysis of receptor redistribution following exposure to CXCL12, BAT1, or plerixafor. Primary CLL cells were incubated with vehicle, 20 mM BAT1, or 20 mM
plerixafor for 3 hours before exposure to CXCL12 for 10 minutes. Control cells were incubated with vehicle alone (no CXCL12). Cells were then stained for membrane and
cytoplasmic CXCR4 to assess its distribution. Unstimulated CLL lymphocytes (top row) express CXCR4 at the cell surface and in the cytoplasm. Binding of CXCL12 causes
receptor internalization with intracellular redistribution, with possible trafficking of cytoplasmic CXCR4 to the membrane (second row). Plerixafor (third row) and BAT1 (bottom
row) bind to surface CXCR4, blocking immunoreactivity, but they do not induce receptor internalization or redistribution. Original magnification 3600 (603 1.4 N.A. objective
lens). Scale bars, 20 mm. (B) Immunoblotting demonstrates BAT1’s antagonism of CXCL12-induced signaling. Primary CLL cells were incubated with BAT1, plerixafor, or
vehicle for 3 hours before exposure to CXCL12 for 10 minutes. Lysates were prepared, and signaling levels were assessed by immunoblotting for ERK phosphorylation
(p-ERK). Incubation with BAT1 led to a dose-dependent reduction in p-ERK, with saturating levels of BAT1 reducing p-ERK to similar levels as 20 mM plerixafor or no stimula-
tion. Densitometric quantification of the blots is shown with adjustment relative to total ERK for each lane. Percentage errors were calculated based on the average variation
between equivalent blots across several experiments. (C) Effects of BAT1 and plerixafor on cell viability were assessed over 24 hours using flow cytometry. Primary CLL cells
were incubated with plerixafor (i) or BAT1 (ii) at a range of concentrations over 24 hours. A progressive decrease in cellular viability was demonstrated at concentrations
exceeding 20 nM BAT1 or plerixafor. Experiments were performed in triplicate, and the mean was taken. Errors are the standard deviation of the mean, added in quadrature to
the standard error on the gating. Curves were fitted using nonlinear regression with software’s in-built log(agonist) vs response curve with variable slope, based on the Hill
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CXCR4 and CXCR7 expression in CLL
It was previously thought that CXCR4 was the sole receptor for
CXCL12, but it has since been found that the scavenger receptor
CXCR7 moderates CXCR4 activation by binding and removing
CXCL12 from the extracellular milieu.35,36 Bis(cyclam) drugs, such
as plerixafor, have been reported to bind to CXCR7, although
binding is reported to be weak.37 To understand the role of CXCR4
and CXCR7 during targeting and antagonism with BAT1 and its
derivatives in CLL, we analyzed the expression of CXCR4 and
CXCR7 by CLL cells and tissues.
Expression of CXCR4 and CXCR7 was demonstrated using
immunohistochemistry (IHC). In normal tonsil, both showed the
expected patterns of reactivity38: CXCR4 showed diffuse positivity
with particular staining of germinal centers, and CXCR7 stained
less strongly but with particular expression in vascular endothelium.
In CLL-infiltrated tissue sections, CXCR4 was expressed through-
out the tissue, although lower expression was observed in the
proliferation centers. Although CXCR7 expression was detected on
CLL lymphocytes, this was weak with no significant differences
between tissue regions (Figure 2A).
To confirm these results, microarray analysis and immunoblotting
were performed for representative cases. Microarray analysis
confirmed the presence of messenger RNA encoding for CXCR7,
but the levels of messenger RNA encoding for CXCR4 were 300-
fold greater. Western blot analysis showed very high levels of
CXCR4, whereas CXCR7 protein levels were very low (Figure 2B).
These results are in accordance with previous reports that found
low or undetectable levels of CXCR7 on CLL cells.17,39 CXCR4
membrane expression in PBMCs was then investigated in 8
patients using flow cytometry (Figure 2C-D). CLL PBMCs were
consistently observed to strongly express CXCR4, but the precise
expression levels varied among cases (Figure 2D).
BAT1 binds with high affinity to CXCR4 on primary
CLL cells
The binding affinity of BAT1 to CXCR4 or CXCR7 present on
primary CLL lymphocytes was assessed by flow cytometry using
antibody competition assays.40 In the case of CXCR4, the
assay revealed a typical competitive-binding curve similar to
the class-leading drug, plerixafor (Figure 3A). The 50% inhibitory
concentration (IC50) of BAT1 was found to be 139 6 3 nM,
higher than that of plerixafor (the measured IC50 for plerixafor in
this assay was 11.7 6 0.7 nM, and the published IC50 is 44
nM41). However, the binding affinity of BAT1 compares favorably
with similarly modified molecules within the bis(cyclam) class,42,43 with
the IC50 and IC90 values of BAT1 well within the reported achievable
plasma levels for plerixafor (achievable and safe plasma concentration
800-1000 ng/mL equivalent to 2 mM44). When the same assay
approach was used to assess binding to CXCR7, neither plerixafor nor
BAT1 caused a significant reduction in antibody attachment to the
cells, suggesting that CXCR4 is the major receptor through which
plerixafor and BAT1 act in primary CLL cells. This observation is in
agreement with the very low expression of CXCR7, and with previous
reports in which plerixafor binding toCXCR7was only observed at very
high concentrations (.10 mM).37
To demonstrate direct targeting of BAT1 to CLL cells, the BAT1-Cy5
conjugate was incubated with the cells, and cellular fluorescence was
assessed using flow cytometry. BAT1-Cy5 showed high affinity for
CXCR4-expressing CLL lymphocytes, and specificity was con-
firmed by inhibition of BAT1-Cy5 binding following incubation of
cells with plerixafor (Figure 3B-C).
BAT1 functions as a CXCL12 antagonist in primary
CLL lymphocytes
Drugs of the bis(cyclam) class are reported to act as pure antagonists
that prevent binding of CXCL12 toCXCR4 but are not internalized and
do not display agonist function.45 Functional assays were used to
confirm that these attributes were retained by BAT1.
First, cytoplasmic and membrane distributions of CXCR4 were
compared using a dual (surface and internal) immunostaining
approach (Figure 4A), which confirmed that CXCR4 was
present across the cell membrane and in the cytoplasm of
untreated CLL lymphocytes. Treatment with CXCL12 led to
cell surface CXCR4 expression becoming reduced and punctate,
with redistribution of the cytoplasmic fraction to a focal region
(Figure 4A, second row). In contrast, incubation with plerixafor
or BAT1 completely blocked staining of the membrane by anti-
CXCR4, confirming that BAT1 binds tightly to CXCR4. Cyto-
plasmic expression and distribution were unaffected following
exposure to BAT1 or plerixafor, suggesting that neither drug was
internalized.
Western blotting was used to confirm that CXCL12-induced
signaling was prevented by BAT1 (Figure 4B). At saturating levels
of BAT1 (20 mM; saturation confirmed by an antibody competition
assay, see Figure 3A), immunoblotting analysis confirmed complete
inhibition of CXCL12-induced ERK1/2 phosphorylation: phosphor-
ylation of ERK1/2 in the presence of BAT1 and CXCL12 was
comparable to that in the absence of CXCL12 or following
plerixafor antagonism at saturating concentrations (Figure 4C). In
a filter-migration assay, .70% reduction in chemotaxis was
observed at saturating doses of BAT1 or plerixafor, equivalent to
migration in the absence of CXCL12 (Figure 4D). In addition, it was
found that BAT1 reduced the viability of CLL lymphocytes at doses
associated with significant receptor blockade (.90% receptor
occupancy), equivalent to the levels observed with plerixafor
(Figure 4B). We suggest that this is likely to be caused by
disrupting the interactions between CLL lymphocytes and the
supportive monocytes present in their culture.20,33
Together, these findings show that, in addition to CXCR4-targeting
activity, BAT1 antagonizes intracellular signal generation, cell
migration, and prosurvival effects of CXCL12. Importantly, we did
not identify any additional toxicity attributable to the modified
structure of the drug compared with plerixafor.
Figure 4. (continued) equation. (D) Inhibition of chemotaxis in response to CXCL12 was assessed using a filter migration assay, where cell migration was assessed using
flow cytometry. BAT1 significantly reduces chemotactic migration of CLL lymphocytes. No significant difference in migration levels was seen between the BAT1-treated cells
and those treated with plerixafor or vehicle alone. ***P , .001, 1-way analysis of variance with the Holm-Sidak multiple-comparisons test. ns, not significant.
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Figure 5. BAT1-cholesterol can be used to decorate fluorescently labeled liposomes, resulting in significantly higher uptake into cells. (A) Illustration of the
prepared liposomes, indicating BAT1-cholesterol decoration of the fluorescently labeled liposomal membrane using the postinsertion method. (B) Liposome sizes were
assessed using DLS. A representative line graph from the analysis is shown: intensity is related to particle size using the Mie scattering function. (C) CXCR4 antibody staining
was used to assess the specificity of liposome binding. Cells were stained with phycoerythrin-CXCR4 antibodies following incubation with bare liposomes (black line) or BAT1-
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BAT1-liposomes bind to CLL lymphocytes with high
affinity and retain CXCL12-blocking function
Liposomes were prepared incorporating a fluorescently labeled
lipid (Figure 1B) to allow tracking. Fluorescent liposomes were
decorated with BAT1-cholesterol using a postinsertion technique34
(Figure 5A).
Various lipid formulations were assessed for their stability and
targeting ability: DOPC (a PL commonly used in liposomes) was
used alone or in combination with 1,2-dimyristoyl-sn-glycero-
3-phospho-L-serine or 1,2-dimyristoyl-sn-glycero-3-phospho-(19-
rac-glycerol), both of which are more strongly negatively charged.
The different lipid formulations were assessed because BAT1 is
cationic, and the increase in liposome surface charge following
its insertion could affect the stability of the liposome suspen-
sion. DLS confirmed that all liposome preparations had hydro-
dynamic radii in the range of 119 to 137 nm (Figure 5B).
Successful insertion of BAT1-cholesterol into the liposomal
membrane was supported by observed changes in the z
potential of the liposomes, which gives an indication of the
surface charge. After incubation with BAT1-cholesterol, the z
potential of every formulation increased significantly (eg, DOPC
liposomes became more positive by 23.2 6 1.5 mV, consistent
with successful insertion of BAT1-cholesterol).
CXCR4 specificity of BAT1-decorated liposomes was assessed
with primary CLL lymphocytes. Antibody staining of CXCR4 was
significantly reduced following cell incubation with BAT1-decorated
liposomes in comparison with undecorated liposomes (Figure 5C).
Furthermore, when cellular migration in response to CXCL12
was tested in the presence or absence of BAT1-decorated
liposomes, it was found that insertion of BAT1-cholesterol into
liposomes did not diminish the function-blocking activity of BAT1
(Figure 5D). Indeed, BAT1-liposomes showed a similar level of
function-blocking activity as plerixafor, reducing migration to the
level observed in the absence of CXCL12. In addition, BAT1-
DOPC liposomes retained their biological effects for up to
4 weeks.
Liposomes were incubated for 3 hours with primary CLL cells at PL
concentrations between 30 and 300 mM, and uptake was assessed
using flow cytometry. All 3 of the BAT1-labeled fluorescent
liposome preparations were preferentially taken up compared with
bare liposomes of the same lipid composition (supplemental
Figure 4). BAT1-DOPC liposomes showed the greatest uptake,
with significantly higher fluorescence observed, even at 30 mM
PL. This result was replicated after a 24-hour coculture with
CD40L murine fibroblasts, which reduce CXCR4 membrane
expression (Figure 5E; supplemental Figures 5 and 6). Laser
deconvolution microscopy images showed TopFluor fluores-
cence present throughout the cell cytoplasm, consistent with
liposome uptake rather than cell membrane binding (Figure 5F).
BAT1-liposomes deliver high levels of doxorubicin
and greater levels of cytotoxicity
Doxorubicin was chosen as a model drug for liposomal encapsu-
lation and delivery. Successful BAT1-cholesterol insertion into dox-
liposomes was supported by changes in their z potential. In HEPES
buffer, the z potential of the bare liposomes was measured to be
22.8 6 1.4 mV, which increased to 24.1 6 1.3 mV following the
addition of cationic BAT1-cholesterol. Liposomal concentrations
from 30 to 300 mM (PL) and time points ranging from 3 to 24 hours
were initially assessed using a representative CLL case. Cell death was
assessed at 24 hours to allow sufficient time for the effects of the
doxorubicin to become apparent; for the earlier incubation time points,
cells were washed to remove liposomes that had not been taken up.
These initial assays showed that incubation with 75 mM liposomes for
only 3 hours led to a significant difference in cell death between BAT1-
labeled liposomes and their bare counterparts; therefore, these
conditions were used in subsequent cell death assays.
Liposomal uptake and cell death were assessed in 10 separate
cases to ensure the robustness and reproducibility of the results and to
control for the variability in levels of CXCR4 expression (Figure 2D).
Flow cytometric analysis confirmed that BAT1-liposomes delivered
significantly higher quantities of doxorubicin, with approximately twofold
greater doxorubicin-associated fluorescence in cells that had died
after treatment with BAT1-labeled liposomes compared with bare
liposomes (Figure 6Bi). Furthermore, BAT1-decorated liposomes
consistently led to increased cell death across the sample set
(Figure 6Bii), with the increase in median cell death from BAT1-
liposomes approximately double that of bare doxorubicin liposome
controls. Fluorescence microscopy was used to investigate the
region to which the doxorubicin had been delivered: at only 3 hours,
DAPI and doxorubicin fluorescence colocalization implied that
doxorubicin had been delivered to the nucleus (Figure 6C).
Discussion
We have developed a novel drug-delivery system, BAT1-liposome,
and showed that it binds with high specificity and affinity to CXCR4.
This allows targeted delivery of therapeutics to CLL cells and blocks
their interaction with the chemoprotective chemokine CXCL12.
When used to deliver doxorubicin, BAT1-liposomes consistently in-
creased CLL cell death compared with undecorated liposomes. The
combination of targeted drug delivery and receptor blockade provided by
BAT1-liposomes is highly attractive in hematology; it has the potential to
deliver an increased local dose of therapeutics while disrupting the
cancer cells’ interaction with their chemoprotective niche.
Clinical relevance, versatility, and modularity were central to the
design of BAT1 and its application in liposomal drug delivery. The
use of CXCR4-targeted drug delivery utilizing a bis(cyclam) motif
has been tested by other investigators: in particular, Oupický and
colleagues developed a range of bis(cyclam)-based polymers
(polymeric-plerixafor) for drug delivery that display CXCR4
Figure 5. (continued) observed between BAT1-decorated liposomes and 20 mM plerixafor or the negative control. Further, no significant difference in migration was observed
between cells incubated with bare liposomes and the positive control. **P , .01, 1-way analysis of variance with the Holm-Sidak multiple-comparisons test. (E) Flow cytometry
was used to quantify levels of liposomal attachment and uptake. At only 30 mM liposomes, the cells incubated with decorated liposomes presented significantly higher levels of
fluorescence (**P , .01, Student t test). (F) Laser deconvolution microscopy was used to show in which region of the cell the liposomes are located after a 3-hour incubation.
Liposomes fluoresce in green, whereas nuclei are labeled with DAPI (blue). Images were prepared by building a z-projection (median intensity) from the image stack comprising
the central region of the cell. The liposomes are observed throughout the cytoplasm. Scale bar, 50 mm.
23 JULY 2019 x VOLUME 3, NUMBER 14 DUAL-ACTION CXCR4-TARGETING LIPOSOMES IN LEUKEMIA 2077
.For personal use only on September 27, 2019. at MANCHESTER ROYAL INFIRMARY www.bloodadvances.orgFrom 
antagonism and are taken up preferentially by CXCR4-overexpressing
cells.26-28,46,47 However, the use of polymeric-plerixafor as the drug-
delivery system introduces some constraints: a balance of CXCR4
affinity, binding of therapeutic agents, and pharmacological behavior
within the body must all be sought from the same material. In contrast,
BAT1 is readily conjugated to fluorescent moieties or cholesterol for
insertion into liposomes, and it retains high efficacy in CXCR4 targeting
and antagonism, demonstrating the versatility of the design approach.
Liposomes were selected because they are the most well-developed
drug-delivery system and are alreadywidely used in clinical practice2,48;
in addition they have been used to encapsulate or complex a wide
range of therapeutics, from small-molecule drugs to biomolecules.49-52
Doxorubicin is an excellent model drug because it is used extensively in
the clinic for cancer treatment in its free and liposomal forms, and it is
inherently fluorescent. However, we believe that BAT1-liposomes are
applicable to a wide range of cargo, the choice of which could be used
to strengthen or tailor the system to its application.
Although the cancer model used in this paper is CLL, the
methodology described should be applicable to a broad range of
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liposomes, with and without BAT1 decoration. (Bi) Liposomal uptake and doxorubicin delivery were determined by assessing the doxorubicin-associated fluorescence in dead
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(C) Cellular localization of the doxorubicin was assessed using laser deconvolution microscopy. Images were prepared by building a z-projection (intensity sum) from the image
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hematological cancers in which CXCR4 is overexpressed. Hema-
tological cancer treatments are limited by the dose that can be
delivered to cancer cells while avoiding bystander cell toxicity. This
can be associated with persistent measurable residual disease,
leading to treatment resistance and disease reemergence.14,33,53,54
Liposomes have the capability to deliver therapeutics at far higher
effective concentrations than would be possible with systemic
delivery. Furthermore, the biology of hematological cancers means
that they are particularly strong targets for liposomal-targeted drug
delivery: liposomes will encounter neoplastic cells during circulation,
and fenestrations in the bone marrow and lymphoid vasculature
allow liposomal extravasation and accumulation in the regions of
interest.55-57 The function-blocking properties of BAT1-liposomes
also mean that cancer cells may be retained in the circulation,
blocked from the CXCL12 gradient that promotes their movement
into the chemoprotective niche and potentially leading to additional
sensitivity to treatment. The use of drug-delivery systems, such as
liposomes, provides unique advantages for the treatment of hemato-
logical disorders, such as CLL, because unlike small-molecule drugs
that must pass through the cell membrane, liposomes can exploit
active uptake through mechanisms such as macropinocytosis,
which is used readily by mature immune cells.58-61
The BAT1-liposome system was designed to incorporate 2
important properties: targeted therapeutic delivery to CXCR4-
overexpressing cells and antagonism against CXCL12, both of
which have now been demonstrated. This dual mechanism differ-
entiates BAT1-liposomes from other targeted drug-delivery systems
that increase selective uptake of a therapeutic agent but do not
have a therapeutic action themselves.7,8 BAT1 tight binding to
CXCR4 was demonstrated alone and following conjugation to
liposomes. Although the receptor redistribution assay demon-
strated that BAT1 alone was a pure antagonist without evidence of
uptake, microscopy showed that BAT1-liposomes were taken up
into the cell. This is in accordance with the literature, because
liposomes and other nanoparticles within the 150 to 200–nm size
range are expected to be endocytosed by lymphocytes through
nonreceptor-mediated routes.59-61 Doxorubicin delivered by lip-
osomes was observed in the cell nuclei, and BAT1-targeted dox-
liposomes caused significantly higher levels of cell death across 10
cases expressing various levels of CXCR4. These results were
despite the fact that neither BAT1-liposomes nor undecorated
(bare) liposomes were stealth coated, which would be expected
to reduce nonspecific uptake.48 Compared with free doxorubicin
at an equivalent concentration, BAT1-liposomes led to increased
cell death (supplemental Figure 10). Furthermore, although free
doxorubicin still produced high levels of cell death, the free drug
cannot show the same selectivity for specific cell types observed
for BAT1-liposomes. In addition to therapeutics delivery, BAT1-
liposomes retained their antagonistic properties: functional blocking
was shown in the inhibition of cellular migration along a CXCL12
gradient. This demonstrates that BAT1-liposomes may be able to
target CXCR4-overexpressing cells and disrupt their interactions
with the chemoprotective niche, thereby sensitizing them to
treatment. In future work, stealth coating could be used to extend
the in vivo circulation time of BAT1-liposomes. Furthermore, the
encapsulation of signal inhibitors or nucleic acids would combine
their strengths with those of the BAT1-liposome system: protecting
sensitive cargo from degradation, allowing higher effective concen-
trations to be delivered, and reducing bystander toxicity.
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28. Wang Y, Li J, Chen Y, Oupický D. Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting
polyplexes. Biomater Sci. 2015;3(7):1114-1123.
29. Misra AC, Luker KE, Durmaz H, Luker GD, Lahann J. CXCR4-targeted nanocarriers for triple negative breast cancers. Biomacromolecules. 2015;16(8):
2412-2417.
30. King A, Ndifon C, Lui S, et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci Adv. 2016;2(5):e1600349.
31. Malvern. The diffusion barrier technique for accurate and reproducible protein mobility measurement. https://particular.ie/wp-content/uploads/2015/07/
AN120906DiffusionBarrierTechnique.pdf. Accessed 30 April 2019.
32. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 2005;391:
71-97.
2080 McCALLION et al 23 JULY 2019 x VOLUME 3, NUMBER 14
.For personal use only on September 27, 2019. at MANCHESTER ROYAL INFIRMARY www.bloodadvances.orgFrom 
33. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from
spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.
34. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new
post-insertion approach. Biochim Biophys Acta. 2001;1513(2):207-216.
35. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling.
Blood. 2009;113(24):6085-6093.
36. Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells
to degrade chemokine ligands. Oncogene. 2010;29(32):4599-4610.
37. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol
Pharmacol. 2009;75(5):1240-1247.
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